Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation.
Panos
George Z
GZ
Lampropoulos
Konstantinos M
KM
Angelousi
Anna G
AG
Charatsis
Gerasimos G
GG
Falagas
Matthew E
ME
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D000077595:Famciclovir; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000201:enzymology / Q000821:virology; D006509:Hepatitis B / Q000150:complications* / Q000188:drug therapy* / Q000201:enzymology / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014775:Virus Activation / Q000187:drug effects
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015075:2-Aminopurine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000077595:Famciclovir